Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life
Siri A. Eikeland, Knut B. Smeland, Floortje Mols, Unn‐Merete Fagerli, Hanne Bersvendsen, Cecilie E. Kiserud, Alexander Fosså
Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin's lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL). MATERIAL AND METHODS: = 606). CIPN associated factors were identified by linear regression analysis. RESULTS: < 0.001). CONCLUSION: HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.